Rachel E. Hayden

The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.

Julian C. Desmond, Joanne C. Mountford, Mark T. Drayson et al. · PubMed · 2003 · 152 citations

Medicine, Oncology, Pharmacology +15

Supramolecular Iron Cylinder with Unprecedented DNA Binding Is a Potent Cytostatic and Apoptotic Agent without Exhibiting Genotoxicity

A.C.G. Hotze, Nikolas J. Hodges, Rachel E. Hayden et al. · Chemistry & Biology · 2008 · 86 citations

Life Sciences, Medicinal Chemistry, Molecular Biology +8

The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis

Jane Birtwistle, Rachel E. Hayden, Farhat L. Khanim et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 2009 · 81 citations

Life Sciences, Biochemistry, Molecular Biology +16

Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia

Farhat L. Khanim, Rachel E. Hayden, Jane Birtwistle et al. · PLoS ONE · 2009 · 73 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

AKR1C Isoforms Represent a Novel Cellular Target for Jasmonates alongside Their Mitochondrial-Mediated Effects

Nicholas Davies, Rachel E. Hayden, Paul J. Simpson et al. · Cancer Research · 2009 · 61 citations

Medicine, Biochemistry, Oncology +13